Navigation Links
Study Details New Molecular Approach to Preventing Alzheimer's
Date:4/24/2008

The concept calls for targeting an enzyme within brain cells

THURSDAY, April 24 (HealthDay News) -- German researchers are reporting a new approach to the possible prevention of the molecular "debris" that's associated with the development of Alzheimer's disease.

The basic idea -- to block the activity of an enzyme called beta-secretase -- is not new, said study lead author Dr. Kai Simons, a professor of cell biology at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden.

A number of laboratories, both academic and commercial, are working on methods to prevent the enzyme from slicing a protein into beta amyloid fragments that form the brain plaques found in people with the disease. All work on the same principle. "If we decrease the amount of cleavage, we could in all likelihood reduce the likelihood of the disease," Simons said.

Most experts now agree that formation of the beta amyloid plaques is directly linked to the development of Alzheimer's. The problem with most proposed methods of blocking beta-secretase, Simons said, is that they are designed to work outside of the affected brain cells.

"This process of cleaving takes place inside cells," he said. "We have constructed an inhibitor which binds outside, on the cell membrane, and goes into the cell where the cleavage occurs."

Reporting in the April 25 issue of the journal Science, Simons and his colleagues described both test-tube experiments and animal studies in which the combination of an anchoring molecule and a beta-secretase inhibitor reduced the formation of beta amyloid plaque by more than 50 percent over four hours, while the inhibitor alone was ineffective.

The success is just one small step toward a medically useful preventive therapy for Alzheimer's disease, Simons acknowledged. For one thing, the treatment was given by injection into the brains of the experimental animals (fruit flies and mice), something not likely to be done with people.

"This is proof of principle," Simons said. "The idea would be to get it into the blood in humans and then over the blood-brain barrier into the brain. There are many ways for molecules to get into the brain."

The blood-brain barrier is a network of tightly packed cells that prevents most molecules from entering the brain.

William J. Netzer, an Alzheimer's researcher at the Fisher Center for Alzheimer's Disease Research Foundation at Rockefeller University in New York City, called the new study "a profoundly interesting line of research."

"It is not implausible that one might improve the effectiveness of a drug by coaxing it to go into a region where the enzymes it blocks exist," Netzer said.

But medical use of such a product can raise questions, he said. "When you put an inhibitor into a living being, the chemical you put in can be modified in the body. Where a compound goes into a cell is a complicated issue when you put it into a human being," he added.

Dr. James Galvin, associate professor of neurology and psychiatry at Washington University in St. Louis, called the German research "a novel idea."

If the concept works, it would solve a puzzle about how to best target the enzyme, Galvin said. And it is a concept with broader medical possibilities, he said.

"You can potentially inhibit other enzymes where cleavage occurs within membranes," he said.

More information

Learn more about Alzheimer's disease from the U.S. Library of Medicine.



SOURCES: Kai Simons, M.D., Ph.D., professor of cell biology, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany; William J. Netzer, Ph.D., research associate, Fisher Center for Alzheimer's Disease Research Foundation, Rockefeller University, New York City; James Galvin, M.D., associate professor of neurology and psychiatry, Washington University, St. Louis; April 25, 2008, Science


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. NSF awards $1.5M for study of in-home health care via wireless networks
2. Study shows positive findings in treating patients with advanced hepatitis C
3. Study finds racial disparities in smoking cessation treatment
4. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
5. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
6. Study finds that competency in colonoscopy requires experience with 150 cases or more
7. Study finds cisplatin less effective than standard treatment for patients with anal cancer
8. Potential viral therapy weapon for difficult cancers is safe and effective in study
9. Study: Counseling trauma victims causes secondary trauma
10. Rat study suggests why teens get hooked on cocaine more easily than adults
11. Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and raise awareness of ... have access to a toilet, even when they’re on their periods. , WaterAid asked over ... results help shine a light on the awkwardness that women face while menstruating, even in ...
(Date:5/24/2016)... MA (PRWEB) , ... May 24, 2016 , ... ... Harvard Medical School, today announced a licensing relationship that will deliver a new ... This relationship will put the medical knowledge and expertise of Harvard Medical ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... of safety signs and safety labels , has been featured ... Symbols: Laser Labels.” , The eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, ...
(Date:5/24/2016)... Conn. (PRWEB) , ... May 24, 2016 , ... After ... . He spent the next decade in hospitals, on medication, living on Social Security ... Look at the Illness and How I Beat It!” (published by Balboa Press), Alexander ...
(Date:5/24/2016)... ... May 24, 2016 , ... Design Concepts , ... Centro del Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was designed ... something special for this often overlooked neighborhood. Located at 609 E. 6th Street, ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended ... adolescents aged 13 years, and above. Effective immediately, the PrePex ... and adolescent males in the 14 priority countries in Southern ... first male circumcision device to receive WHO Prequalification on 31 ... said: " The expanded use of PrePex ...
(Date:5/23/2016)... -- Gamida Cell, a leader in cellular ... orphan genetic diseases, announced today it has been awarded ... Israel Innovation Authority (formerly the Office of the Chief ... The mission of the Israel Innovation Authority is to ... and technology, while stimulating economic growth. The ...
(Date:5/22/2016)... DUBLIN , May 23, 2016 ... to develop its anti-fibrotic and anti-inflammatory compound DS102 ... well as in non-alcoholic steatohepatitis (NASH) patients. ... is significantly sequestered in lung tissue and has ... tissue after oral administration. The Company will publish ...
Breaking Medicine Technology: